Last Friday, shares in Oklahoma City, Oklahoma headquartered Paycom Software Inc. ended the day 0.46% lower at $49.70. The stock recorded a trading volume of 318,558 shares. The Company's shares have advanced 1.76% in the last one month, 6.40% in the previous three months, and 32.08% since the start of this year. The stock is trading above its 200-day moving average by 23.43%. Furthermore, shares of Paycom Software, which provides cloud-based human capital management (HCM) software solutions delivered as-Software-as-a-Service for small to mid-sized companies in the US, have a Relative Strength Index (RSI) of 50.53.
On September 30th, 2016, research firm RBC Capital Markets initiated a 'Sector Perform' rating on the Company's stock, issuing a target price of $54 per share.
As per notes filed with the SEC on October 06th, 2016, the Board of Directors of Paycom Software approved and adopted on October 4th, 2016, new forms of award agreements for grants of restricted stock under the Paycom Software, Inc. 2014 Long-Term Incentive Plan to its chief executive officer, other named executive officers and non-executives, and non-sales employees. Access our complete research report on PAYC for free at:
South San Francisco, California headquartered Innoviva Inc.'s stock finished Friday's session 1.77% lower at $9.97 with a total trading volume of 342,843 shares. The Company's shares have gained 19.12% on an YTD basis. The stock is trading below its 50-day moving average by 12.68%. Moreover, shares of Innoviva, which engages in the development and commercialization of bio-pharmaceuticals, have an RSI of 29.70.
On September 06th, 2016, GlaxoSmithKline PLC and Innoviva announced the presentation of further data from the pivotal phase III FULFIL study with investigational closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. The study, which reported headline results in June 2016, met its two co-primary endpoints. At 24 weeks, there was a clinically meaningful and statistically significant (p<0.001) benefit for FF/UMEC/VI in both lung function, measured as mean change from baseline in trough FEV1 and health-related quality of life, measured as mean change from baseline in St George's Respiratory Questionnaire (SGRQ) total score. Additionally, the proportion of patients who responded with the minimum clinically important difference in SGRQ (-4 units) was 50% on closed triple and 41% on budesonide/formoterol. The complimentary research report on INVA can be downloaded at:
Shares in Atlanta, Georgia headquartered Manhattan Associates Inc. ended the session 0.92% lower at $56.78. The stock recorded a trading volume of 894,718 shares, which was above its three months average volume of 605,040 shares. The Company's shares are trading below their 50-day moving average by 3.60%. Moreover, shares of Manhattan Associates, which develops, sells, deploys, services, and maintains software solutions to manage supply chains, inventory, and omni-channel operations for retailers, wholesalers, manufacturers, logistics providers, and other organizations, have an RSI of 44.37.
On October 04th, 2016, Manhattan Associates announced that ID Logistics, a market leader in contract logistics services, has selected Manhattan's Warehouse Management Solution to help expand its business. While the investment will initially support the company's further penetration of the pharmaceuticals sector, ID Logistics expects the Manhattan solution will enable expansion into new business and geographical sectors. Register for free on Stock-Callers.com and get access to the latest PDF format report on MANH at:
Sunnyvale, California headquartered Proofpoint Inc.'s shares recorded a trading volume of 613,167 shares, which was higher than their three months average volume of 589,100 shares. The stock closed 0.66% higher at $70.52. The Company's shares have advanced 5.25% in the previous three months and 8.48% on an YTD basis. The stock is trading 14.89% above its 200-day moving average. Additionally, shares of Proofpoint, which provides threat protection, incident response, regulatory compliance, archiving, governance, eDiscovery, and secure communication solutions worldwide, have an RSI of 36.11.
On October 03rd, 2016, Proofpoint announced that it will report its financial results for Q3 2016 after the close of the market on October 20th, 2016. Proofpoint will host a conference call and live webcast to discuss those financial results for investors and analysts at 4:30 p.m. ET on October 20th, 2016. Download your free research report on PFPT at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA